Recursion Pharmaceuticals (RXRX), an AI-driven biotechnology company focused on drug discovery, demonstrates strong compliance in business activities and low debt levels but faces challenges due to elevated interest income from investments, exceeding Shariah thresholds. Financial screening reveals passes on debt and liquidity ratios across major standards, but failure on non-compliant income purification requirements. No controversies or non-permissible activities identified, with positive ESG alignment. Overall, while the core business is halal, financial impurities require significant purification. Investors should monitor for improvements in income sources.